Variant Bio names Dr. Craig Basson as Chief Medical Officer to oversee clinical development strategy

USA—Variant Bio, a genomics-driven artificial intelligence drug discovery company based in the United States, has announced a significant addition to its executive leadership team.

The company has appointed Craig T. Basson, MD, PhD, to serve as Chief Medical Officer and President of Research and Development, bringing extensive experience in pharmaceutical development and translational medicine to the organization.

Extensive Background in Drug Development

Dr. Basson joins Variant Bio with more than 25 years of leadership experience spanning academic medicine, global pharmaceutical development, and biotechnology sectors.

His expertise encompasses cardiovascular disease, metabolic disorders, human genetics, and translational science, positioning him as a valuable asset for the company’s mission to advance genomics-informed therapeutics.

Before joining Variant Bio, Dr. Basson held the position of Chief Medical Officer at Bitterroot Bio, a cardio-immunology-focused company.

During his tenure there, he developed the clinical development strategy from the ground up and successfully accelerated the lead program through Phase 1 clinical testing into Phase 2 trials.

Leadership Across Multiple Organizations

Dr. Basson’s career also includes a pivotal role at Boston Pharmaceuticals, where he served as co-chief medical officer.

In this capacity, he helped transform the organization from an early-stage startup into a multi-program clinical biotechnology company.

He oversaw development programs across general medicine and oncology, maintained close collaboration with the U.S. Food and Drug Administration, and eventually stepped into the role of interim Chief Executive Officer.

His pharmaceutical industry experience includes a decade-long tenure at Novartis, which began in 2010.

He initially joined as Global Head of Cardiovascular Translational Medicine before advancing to lead the combined Cardiovascular and Metabolism early development organization.

During this period, his teams supported more than ten successful proof-of-concept studies and helped advance multiple therapies through the development pipeline, including notable treatments such as Entresto, Leqvio, Ilaris, and pelacarsen.

He also played a contributing role in major outcomes programs, including the landmark CANTOS trial.

Academic Credentials and Recognition

Dr. Basson earned both his medical degree and doctor of philosophy at Yale University.

He completed his medical training at Johns Hopkins University and Brigham and Women’s Hospital, establishing a strong foundation in clinical medicine and research.

He subsequently spent 14 years at Weill Cornell Medicine, where he led groundbreaking research on the genetic basis of cardiovascular disease.

His contributions to the field earned him election to the American Society of Clinical Investigation and designation as an Established Investigator by the American Heart Association.

Strategic Vision for Variant Bio

In his new role at Variant Bio, Dr. Basson will direct research initiatives and lead the company’s clinical strategy and development efforts.

He will focus on advancing therapeutics informed by the company’s Inference AI discovery platform and insights derived from studies conducted with diverse populations around the world.

Andrew Farnum, Chief Executive Officer of Variant Bio, expressed enthusiasm about the appointment, noting that Dr. Basson’s career uniquely combines deep expertise in human genetics, rigorous clinical science, and successful large-scale drug development.

Farnum emphasized that Dr. Basson’s leadership and experience in translating genetic insights into medicines will prove instrumental as the company advances its programs into clinical testing.

Dr. Basson shared his perspective on joining Variant Bio, highlighting the company’s capability to uncover actionable insights from large-scale human genomics data.

He described this as a powerful opportunity to improve the way medicines are discovered and developed, expressing excitement about helping translate this science into meaningful benefits for patients worldwide.